Nilsine Partners LLC Trims Stake in Johnson & Johnson (NYSE:JNJ)

Nilsine Partners LLC trimmed its stake in Johnson & Johnson (NYSE:JNJ) by 11.2% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,170 shares of the company’s stock after selling 2,422 shares during the period. Nilsine Partners LLC’s holdings in Johnson & Johnson were worth $3,005,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Moneta Group Investment Advisors LLC boosted its holdings in Johnson & Johnson by 90,144.4% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock worth $9,607,414,000 after buying an additional 54,326,454 shares during the period. Morgan Stanley boosted its holdings in Johnson & Johnson by 12.0% in the 4th quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock worth $7,458,962,000 after buying an additional 4,521,062 shares during the period. Norges Bank bought a new position in Johnson & Johnson in the 4th quarter worth $4,609,399,000. Charles Schwab Investment Management Inc. boosted its holdings in Johnson & Johnson by 1.9% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 17,189,229 shares of the company’s stock worth $3,046,449,000 after buying an additional 328,297 shares during the period. Finally, Barclays PLC boosted its holdings in Johnson & Johnson by 61.0% in the 2nd quarter. Barclays PLC now owns 11,287,765 shares of the company’s stock worth $1,868,351,000 after buying an additional 4,278,512 shares during the period. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Up 0.5 %

Shares of NYSE JNJ opened at $152.31 on Wednesday. The firm’s 50-day moving average price is $157.79 and its 200-day moving average price is $156.18. The company has a current ratio of 1.16, a quick ratio of 0.91 and a debt-to-equity ratio of 0.38. The stock has a market capitalization of $367.03 billion, a price-to-earnings ratio of 11.03, a P/E/G ratio of 2.56 and a beta of 0.53. Johnson & Johnson has a 12-month low of $144.95 and a 12-month high of $175.97.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, January 23rd. The company reported $2.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.28 by $0.01. The firm had revenue of $21.40 billion for the quarter, compared to analysts’ expectations of $21.02 billion. Johnson & Johnson had a net margin of 37.79% and a return on equity of 37.27%. The business’s revenue was down 9.7% compared to the same quarter last year. During the same period in the prior year, the company earned $2.35 EPS. On average, equities research analysts anticipate that Johnson & Johnson will post 10.65 EPS for the current fiscal year.

Analysts Set New Price Targets

JNJ has been the subject of several recent analyst reports. Morgan Stanley dropped their target price on shares of Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating for the company in a report on Wednesday, January 24th. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a report on Wednesday, March 13th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, February 6th. Raymond James increased their price objective on shares of Johnson & Johnson from $172.00 to $175.00 and gave the company an “outperform” rating in a report on Wednesday, January 3rd. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $181.00 price objective on shares of Johnson & Johnson in a report on Wednesday, February 28th. Seven equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $177.31.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 59,397 shares of the firm’s stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $156.27, for a total value of $9,281,969.19. Following the completion of the sale, the executive vice president now owns 141,416 shares of the company’s stock, valued at $22,099,078.32. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 59,397 shares of the firm’s stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $156.27, for a total value of $9,281,969.19. Following the completion of the sale, the executive vice president now owns 141,416 shares of the company’s stock, valued at $22,099,078.32. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, major shareholder & Johnson Johnson sold 3,725 shares of the firm’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the sale, the insider now directly owns 4,099,575 shares of the company’s stock, valued at approximately $105,810,030.75. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.